
-
Djokovic, Sinner on Wimbledon collision course
-
Vaughan says Crawley 'lucky' to have so many England caps
-
Russian forces claim first foothold in new Ukraine region
-
US envoy says satisfied with Lebanese response on disarming of Hezbollah
-
European stocks, dollar firm as US tariff deadline looms
-
Wimbledon blames 'human error' for embarrassing line-calling glitch
-
Three things learned from British Grand Prix
-
NGOs laud tougher Malaysia plastic trash import laws
-
Mulder makes highest South Africa Test score
-
UK marks London 7/7 attacks as king hails 'spirit of unity'
-
Apple appeals 500-mn-euro EU fine
-
Crowds celebrate Nepal ex-king's birthday in show of support
-
Bali flights nixed after huge Indonesia volcano eruption
-
Hamas, Israel resume talks as Netanyahu set to meet Trump
-
Hong Kong fans queue for opening of Cristiano Ronaldo exhibition
-
Itoje back as Lions take no chances against ACT Brumbies
-
Stock markets struggle as Trump's tariff deadline looms
-
Nearly 450,000 Afghans left Iran since June 1: IOM
-
North Korea bars Western influencers from trade fair tour
-
Typhoon Danas kills two, injures hundreds in Taiwan
-
Dutch coastal village turns to tech to find lost fishermen
-
Boxer Chavez's appeal against arrest if deported from US rejected: Mexico prosecutor
-
India captain Gill hailed back home after 'brilliant' Test win
-
The making of Australia's mushroom murders
-
Indonesia volcano spews 18-kilometre ash tower
-
Youthful Chelsea ready for Thiago Silva reunion at Club World Cup
-
Australian inquiry cites racism in Indigenous shooting
-
Djokovic wary despite Wimbledon form, dominant Sinner faces Dimitrov
-
Australian woman found guilty of triple murder with toxic mushrooms
-
Indonesia volcano spews 18-kilometre ash tower: agency
-
Trump says to send first tariff letters on Monday
-
The strange case of Evgeniya Mayboroda, Russia's rebel retiree
-
Asian markets drop as Trump's tariff deadline looms
-
Under-strength Brumbies eye 'big opportunity' against Lions
-
Macron to rekindle relationship with Francophile King Charles on UK visit
-
Trump hosts Netanyahu, hopes for Israel-Hamas deal 'this week'
-
Pressed to confess: Japan accused of 'hostage justice'
-
Demna to bow out at Balenciaga in Paris Haute Couture Week
-
Host of internationals in Australia-New Zealand squad to face Lions
-
Egyptian conservators give King Tut's treasures new glow
-
Mexico defeat USA 2-1 to retain CONCACAF Gold Cup
-
Visa's 24/7 war room takes on global cybercriminals
-
BRICS nations slam Trump tariffs, condemn strikes on Iran
-
Bausch Health's Gastroenterology Business, Salix Pharmaceuticals, Launches Fresh "I Wish I Knew" Campaign to Educate People About Xifaxan(R) (rifaximin) for Adults at Risk of Overt Hepatic Encephalopathy Recurrence
-
Medical Care Technologies (OTC: MDCE) Unveils Bold Vision for Mobile Self-Care Innovation
-
Living Security Launches "Free Summer Content Series" to Keep Cybersecurity Awareness Hot All Season Long
-
GameSquare Experiences to Produce the 2025 100 Thieves Summer Block Party Presented by Lexus
-
Western Announces New Chief Financial Officer
-
Survey Reveals Renewed Optimism in SPAC Market Despite Lingering Challenges
-
IRS Launches 2025 Identity Theft Campaign - Clear Start Tax Urges Tax Pros and Clients to Take Action

US panel weighs authorizing Covid vaccines for youngest children
After months of anxious wait for some parents, a panel of experts convened by the US Food and Drug Administration will meet Wednesday to weigh recommending Covid vaccines for the nation's youngest children.
Children under five are the only age group not yet eligible for Covid immunization in the United States and most other countries. If, as expected, panelists vote in favor of greenlighting the Pfizer and Moderna vaccines, formal authorizations should follow quickly, with the first shots in arms expected by next week.
Ahead of the meeting, the FDA posted its independent analyses of the two drugs, deeming both safe and effective. It also said there was a pressing unmet need to inoculate children in the age group since their rates of hospitalization and death "are higher than among children and adolescents 5-17 years of age."
Both vaccines are based on messenger RNA technology, which delivers genetic code for the coronavirus spike protein to human cells, training the immune system to be ready for when it encounters the real virus.
Pfizer is seeking authorization for three doses at three micrograms given to ages six months through four years, while Moderna has asked for the FDA to approve its vaccine as two doses of a higher 30 micrograms, for ages six months through five years.
They were tested in trials of thousands of children where they were found to have similar levels of mild effects to older age groups and triggered similar levels of antibodies.
Efficacy against infection was higher for Pfizer, with the company placing it at 80 percent compared to Moderna's estimates of 51 percent in the six-month-old to age two group and 37 percent in the two to five years age group.
But the figures are provisional and Moderna is studying adding a third dose later that may increase its figures.
There are some 20 million US children aged four years and under. If the FDA-appointed experts recommend the two vaccines, then the matter will go to another committee convened by the Centers for Disease Control and Prevention for a final say.
White House officials last week said the rollout of millions of shots at pharmacies and doctors' offices could begin as soon as June 21, following the Juneteenth holiday on June 20.
Of the total US Covid deaths, 480 have come in children under five, according to the latest official data.
Obesity, neurological disorders and asthma are associated with increased risk of severe disease, "however, a majority of children hospitalized for Covid-19 have no underlying medical conditions," the FDA said in a document.
Children can also go on to contract multisystem inflammatory syndrome in children (MIS-C), a rare but serious post-viral condition.
Data on long Covid in children is sparse, but the FDA's document cited a national survey in the United Kingdom which found that "among children ages two to 11 years who tested positive for COVID-19, 7.2 percent reported continued symptoms at 12 weeks."
L.Durand--AMWN